- Home
- ELDN vs LFCR Comparison
ELDN vs LFCR Comparison
Compare ELDN & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- LFCR
- Stock Information
- Founded
- ELDN 2004
- LFCR 1986
- Country
- ELDN United States
- LFCR United States
- Employees
- ELDN N/A
- LFCR N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- LFCR Health Care
- Exchange
- ELDN Nasdaq
- LFCR Nasdaq
- Market Cap
- ELDN 178.4M
- LFCR N/A
- IPO Year
- ELDN N/A
- LFCR N/A
- Fundamental
- Price
- ELDN $3.17
- LFCR $6.89
- Analyst Decision
- ELDN Strong Buy
- LFCR Buy
- Analyst Count
- ELDN 1
- LFCR 3
- Target Price
- ELDN $16.00
- LFCR $8.00
- AVG Volume (30 Days)
- ELDN 150.4K
- LFCR 225.0K
- Earning Date
- ELDN 05-20-2025
- LFCR 04-03-2025
- Dividend Yield
- ELDN N/A
- LFCR N/A
- EPS Growth
- ELDN N/A
- LFCR N/A
- EPS
- ELDN N/A
- LFCR N/A
- Revenue
- ELDN N/A
- LFCR $130,309,000.00
- Revenue This Year
- ELDN N/A
- LFCR $1.57
- Revenue Next Year
- ELDN N/A
- LFCR $3.98
- P/E Ratio
- ELDN N/A
- LFCR N/A
- Revenue Growth
- ELDN N/A
- LFCR 7.23
- 52 Week Low
- ELDN $2.00
- LFCR $3.68
- 52 Week High
- ELDN $5.54
- LFCR $7.99
- Technical
- Relative Strength Index (RSI)
- ELDN 48.82
- LFCR 56.58
- Support Level
- ELDN $2.85
- LFCR $6.73
- Resistance Level
- ELDN $3.51
- LFCR $7.48
- Average True Range (ATR)
- ELDN 0.25
- LFCR 0.37
- MACD
- ELDN 0.01
- LFCR 0.07
- Stochastic Oscillator
- ELDN 45.07
- LFCR 62.18
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.